Global Emphysema Market Size, Share, and Trends Analysis Report – Industry Overview and Forecast to 2033

Emphysema Market Size

• The global emphysema market size was valued at USD 3.44 billion in 2025 and is expected to reach USD 5.69 billion by 2033, at a CAGR of 6.50% during the forecast period
• The market growth is largely fueled by the increasing prevalence of chronic respiratory diseases, particularly chronic obstructive pulmonary disease (COPD), along with rising exposure to risk factors such as smoking, air pollution, and occupational hazards, leading to a higher patient pool globally
• Furthermore, growing demand for advanced treatment options, including bronchodilators, corticosteroids, oxygen therapy, and minimally invasive surgical interventions, coupled with improvements in diagnostic capabilities and healthcare infrastructure, is establishing emphysema therapies as essential components of respiratory care. These converging factors are accelerating the adoption of emphysema treatment solutions, thereby significantly boosting the industry's growth

Emphysema Market Analysis

• Emphysema, a chronic progressive lung disease characterized by damage to the alveoli and reduced respiratory function, represents a critical segment of chronic obstructive pulmonary disease (COPD) management, requiring long-term therapeutic interventions and continuous monitoring across hospital, clinical, and homecare settings due to its impact on breathing capacity and overall quality of life
• The escalating demand for emphysema treatment is primarily fueled by the rising global prevalence of COPD, increasing exposure to risk factors such as tobacco smoking, air pollution, and occupational hazards, along with growing awareness, early diagnosis, and advancements in respiratory care technologies
• North America dominated the emphysema market with the largest revenue share of 38.7% in 2025, characterized by advanced healthcare infrastructure, high diagnosis rates, and strong adoption of innovative treatment options, with the U.S. experiencing substantial growth driven by increasing healthcare expenditure and availability of combination drug therapies and minimally invasive procedures
• Asia-Pacific is expected to be the fastest growing region in the emphysema market during the forecast period due to rising pollution levels, expanding patient population, improving healthcare infrastructure, and increasing awareness regarding respiratory diseases and their management
• Medication segment dominated the emphysema market with a market share of 44.3% in 2025, driven by its widespread use as the primary line of treatment, including bronchodilators, corticosteroids, and combination therapies aimed at symptom control and disease progression management

Report Scope and Emphysema Market Segmentation

Emphysema Market Trends

“Advancements in Targeted Therapies and Minimally Invasive Interventions”

• A significant and accelerating trend in the global emphysema market is the growing adoption of targeted pharmacological therapies and minimally invasive treatment approaches such as endobronchial valve therapy and lung volume reduction procedures. This combination of innovations is significantly improving patient outcomes and quality of life
• For instance, the Zephyr Endobronchial Valve by Pulmonx is increasingly being used as a minimally invasive option for patients with severe emphysema, helping to improve lung function without the need for major surgery. Similarly, Spiration Valve System offers bronchoscopic treatment alternatives for eligible patients
• Technological advancements in treatment enable features such as precise targeting of damaged lung areas, improved airflow, and reduced hyperinflation, leading to better disease management. For instance, newer biologic therapies under development aim to target inflammatory pathways associated with COPD and emphysema progression. Furthermore, improved imaging and diagnostic tools allow clinicians to identify suitable candidates for advanced therapies more effectively
• The integration of advanced diagnostics with personalized treatment approaches facilitates better clinical decision-making and optimized patient care. Through coordinated care systems, healthcare providers can manage emphysema alongside other respiratory and chronic conditions, creating a more comprehensive treatment ecosystem
• This trend towards more effective, less invasive, and patient-centric treatment solutions is fundamentally reshaping expectations in respiratory care. Consequently, companies such as Pulmonx and Olympus Corporation are developing innovative devices and therapies aimed at improving treatment precision and patient outcomes
• The demand for advanced emphysema treatment options that offer improved efficacy and reduced recovery times is growing rapidly across healthcare systems, as patients and providers increasingly prioritize better disease management and quality of life
• Growing focus on combination therapies integrating pharmacological and non-pharmacological approaches, including pulmonary rehabilitation programs, is enhancing treatment effectiveness and long-term patient outcomes

Emphysema Market Dynamics

Driver

“Rising Disease Burden and Increasing Awareness of Respiratory Health”

• The increasing prevalence of chronic respiratory diseases, particularly COPD and emphysema, coupled with growing awareness regarding early diagnosis and treatment, is a significant driver for the heightened demand for emphysema therapies
• For instance, in March 2025, GlaxoSmithKline plc announced continued expansion of its respiratory portfolio with advanced inhalation therapies targeting COPD management, reflecting ongoing innovation in the treatment landscape. Such strategies by key companies are expected to drive the emphysema market growth in the forecast period
• As populations age and exposure to risk factors such as smoking and air pollution rises, patients increasingly seek effective long-term treatment options, leading to greater adoption of medications, oxygen therapy, and surgical interventions
• Furthermore, improvements in healthcare infrastructure and diagnostic capabilities are enabling earlier detection and better disease management, which is increasing treatment uptake globally
• The availability of combination therapies, home-based care solutions, and supportive technologies such as portable oxygen devices are key factors propelling the adoption of emphysema treatments across hospital and homecare settings. The shift toward patient-centric care and chronic disease management further contributes to market growth
• Increasing government initiatives and public health programs focused on reducing smoking rates and improving air quality are indirectly supporting early diagnosis and treatment adoption, thereby contributing to market expansion
• Rising investments in research and development by pharmaceutical and biotechnology companies are accelerating the introduction of innovative therapies, further driving market growth

Restraint/Challenge

“High Treatment Costs and Limited Disease Reversibility”

• Concerns surrounding the high cost of advanced emphysema treatments and limited curative options pose a significant challenge to broader market growth. As emphysema is a progressive and irreversible disease, long-term treatment costs can be substantial, raising affordability concerns among patients
• For instance, high costs associated with procedures such as lung volume reduction surgery and endobronchial valve therapy have made access difficult for patients in low- and middle-income regions, limiting widespread adoption
• Addressing these cost-related challenges through improved reimbursement policies, cost-effective treatment alternatives, and expanded healthcare coverage is crucial for enhancing accessibility. Companies such as Boehringer Ingelheim and AstraZeneca are focusing on developing more efficient therapies to balance cost and effectiveness. Additionally, limited awareness and underdiagnosis in certain regions remain barriers to timely treatment initiation
• While healthcare systems are improving globally, disparities in access to advanced treatments and specialized care continue to hinder optimal disease management, particularly in developing economies
• Overcoming these challenges through increased investment in healthcare infrastructure, patient education, and development of affordable therapeutic options will be vital for sustained market growth
• Stringent regulatory requirements and lengthy approval timelines for novel therapies and medical devices can delay market entry and limit the availability of innovative treatment options
• Potential side effects and complications associated with long-term medication use and surgical interventions may reduce patient adherence and impact overall treatment outcomes

Emphysema Market Scope

The market is segmented on the basis of type, diagnosis, complications, treatment, route of administration, end-users, and distribution channel.

• By Type

On the basis of type, the emphysema market is segmented into centriacinar, panacinar, paraseptal, and others. The centriacinar segment dominated the market with the largest revenue share in 2025, driven by its strong association with smoking-related lung damage, which represents the most common cause of emphysema globally. This type predominantly affects the upper lobes of the lungs and is widely diagnosed among long-term smokers, contributing significantly to patient volume. The higher prevalence of smoking in both developed and developing countries further supports the dominance of this segment. Additionally, increased awareness, screening programs, and early diagnosis of smoking-related respiratory diseases have led to higher treatment adoption. Pharmaceutical companies also focus heavily on therapies targeting this segment due to its large patient base. As a result, centriacinar emphysema continues to account for the majority of treatment demand.

The panacinar segment is anticipated to witness the fastest growth rate from 2026 to 2033, fueled by increasing diagnosis of genetic conditions such as alpha-1 antitrypsin deficiency. This type affects the entire alveolus uniformly and is often identified in younger patient populations compared to other forms. Growing advancements in genetic testing and diagnostic tools are enabling earlier and more accurate detection of panacinar emphysema. Additionally, rising awareness of rare respiratory diseases and increasing availability of targeted therapies are contributing to segment growth. Healthcare providers are increasingly focusing on personalized treatment approaches for such conditions. These factors collectively drive the rapid expansion of the panacinar segment in the forecast period.

• By Diagnosis

On the basis of diagnosis, the emphysema market is segmented into imaging test, lab test, spirometry, and others. The imaging test segment dominated the market with the largest revenue share in 2025, driven by the widespread use of chest X-rays and CT scans for accurate visualization of lung damage. Imaging techniques provide detailed insights into the structure and severity of emphysema, making them essential for diagnosis and treatment planning. The increasing availability of advanced imaging technologies in hospitals and diagnostic centers further supports segment dominance. Physicians rely heavily on imaging for confirming emphysema and differentiating it from other respiratory conditions. Additionally, technological advancements such as high-resolution CT scans have improved diagnostic accuracy. These factors contribute to the strong position of imaging tests in the market.

The spirometry segment is expected to witness the fastest growth rate from 2026 to 2033, driven by its cost-effectiveness and ease of use in both clinical and primary care settings. Spirometry is widely used for early detection and monitoring of lung function, making it a key tool in managing emphysema. Increasing awareness about preventive healthcare and routine lung function testing is boosting its adoption. Additionally, portable spirometry devices are gaining popularity, especially in homecare and remote monitoring settings. Government initiatives promoting early diagnosis of respiratory diseases are further supporting segment growth. As a result, spirometry is emerging as a rapidly expanding diagnostic approach.

• By Complications

On the basis of complications, the emphysema market is segmented into chest infections, collapsed lung (pneumothorax), heart problems, lungs hole (bullae), and others. The chest infections segment dominated the market with the largest revenue share in 2025, driven by the high susceptibility of emphysema patients to recurrent respiratory infections. Damaged lung tissues and weakened immunity increase the risk of infections, leading to frequent hospitalizations and treatment requirements. This segment sees significant demand for antibiotics and supportive therapies. Additionally, aging populations and comorbid conditions further contribute to the prevalence of chest infections. Healthcare providers prioritize infection management as a critical component of emphysema care. These factors collectively drive the dominance of this segment.

The collapsed lung (pneumothorax) segment is anticipated to witness the fastest growth rate from 2026 to 2033, fueled by increasing incidence of severe emphysema cases and advanced disease progression. Pneumothorax is a serious complication requiring immediate medical intervention, leading to higher treatment demand. Improvements in diagnostic imaging and emergency care are enabling faster detection and management. Additionally, rising awareness among clinicians about managing acute complications is contributing to segment growth. The availability of minimally invasive procedures for treatment further supports adoption. These factors are expected to drive rapid growth in this segment.

• By Treatment

On the basis of treatment, the emphysema market is segmented into medication, therapy, surgery, and others. The medication segment dominated the market with the largest revenue share of 44.3% in 2025, driven by its role as the first-line treatment option for managing symptoms and slowing disease progression. Common medications such as bronchodilators, corticosteroids, and combination inhalers are widely prescribed across all stages of the disease. The ease of administration and widespread availability of these drugs contribute to their high adoption. Additionally, continuous advancements in inhalation therapies and drug formulations are enhancing treatment effectiveness. Pharmaceutical companies are actively investing in developing new drugs to improve patient outcomes. These factors solidify the dominance of the medication segment.

The surgery segment is expected to witness the fastest growth rate from 2026 to 2033, driven by increasing adoption of advanced procedures such as lung volume reduction surgery and lung transplantation. These interventions are particularly beneficial for patients with severe emphysema who do not respond to conventional therapies. Technological advancements and improved surgical outcomes are encouraging more patients to opt for these procedures. Additionally, the growing availability of minimally invasive techniques is reducing recovery time and associated risks. Healthcare systems are increasingly supporting such advanced treatments. These factors contribute to the rapid growth of the surgery segment.

• By Route of Administration

On the basis of route of administration, the emphysema market is segmented into oral, parenteral, inhalation, and others. The inhalation segment dominated the market with the largest revenue share in 2025, driven by its direct delivery of medication to the lungs, ensuring rapid and effective symptom relief. Inhalers and nebulizers are widely used due to their efficiency and reduced systemic side effects. The convenience and ease of use of inhalation devices further support their widespread adoption. Additionally, advancements in inhaler technology are improving drug delivery and patient compliance. Healthcare providers strongly prefer this route for managing chronic respiratory conditions. These factors contribute to its leading position in the market.

The parenteral segment is anticipated to witness the fastest growth rate from 2026 to 2033, fueled by increasing use in acute care settings and severe cases requiring immediate intervention. Parenteral administration allows rapid drug delivery, making it suitable for emergency situations. The rising prevalence of hospital admissions due to exacerbations is supporting segment growth. Additionally, ongoing research into injectable biologics and advanced therapies is expanding its applications. Healthcare providers are increasingly adopting this route for critical care management. These factors drive the growth of the parenteral segment.

• By End-Users

On the basis of end-users, the emphysema market is segmented into hospitals, homecare, speciality centres, and others. The hospitals segment dominated the market with the largest revenue share in 2025, driven by the availability of advanced diagnostic and treatment facilities. Hospitals serve as primary centers for managing severe cases and complications associated with emphysema. The presence of skilled healthcare professionals and access to emergency care further support segment dominance. Additionally, increasing hospital admissions due to disease exacerbations contribute to higher demand. Hospitals also play a key role in surgical interventions and advanced therapies. These factors collectively drive the dominance of this segment.

The homecare segment is expected to witness the fastest growth rate from 2026 to 2033, fueled by the growing preference for at-home treatment and long-term disease management. Homecare solutions such as portable oxygen therapy and remote monitoring devices are gaining popularity among patients. The rising focus on reducing hospital stays and healthcare costs is further supporting this trend. Additionally, advancements in telemedicine and digital health technologies are enhancing home-based care. Patients increasingly prefer the comfort and convenience of receiving treatment at home. These factors contribute to the rapid expansion of the homecare segment.

• By Distribution Channel

On the basis of distribution channel, the emphysema market is segmented into hospital pharmacy, online pharmacy, and retail pharmacy. The hospital pharmacy segment dominated the market with the largest revenue share in 2025, driven by the high volume of prescriptions generated in hospital settings. Patients undergoing treatment in hospitals rely on in-house pharmacies for immediate access to medications. The availability of specialized drugs and professional guidance further supports segment dominance. Additionally, hospital pharmacies play a crucial role in managing acute and severe cases. These factors contribute to their leading position in the market.

The online pharmacy segment is anticipated to witness the fastest growth rate from 2026 to 2033, fueled by the increasing adoption of e-commerce platforms and digital healthcare solutions. Online pharmacies offer convenience, home delivery, and competitive pricing, making them attractive to patients with chronic conditions. The growing penetration of smartphones and internet access is further supporting this trend. Additionally, regulatory support for digital health platforms is boosting market growth. Patients increasingly prefer online channels for recurring medication purchases. These factors drive the rapid expansion of the online pharmacy segment.

Emphysema Market Regional Analysis

• North America dominated the emphysema market with the largest revenue share of 38.7% in 2025, characterized by advanced healthcare infrastructure, high diagnosis rates, and strong adoption of innovative treatment options
• Patients in the region highly benefit from the availability of advanced diagnostic technologies, effective treatment options, and well-established healthcare systems supporting respiratory care and disease management
• This widespread treatment adoption is further supported by high healthcare expenditure, a strong presence of key pharmaceutical companies, and the growing focus on innovative therapies and long-term disease management, establishing emphysema treatment as a critical component of respiratory healthcare in both hospital and homecare settings

U.S. Emphysema Market Insight

The U.S. emphysema market captured the largest revenue share of 79% in 2025 within North America, fueled by the high prevalence of COPD, strong healthcare infrastructure, and advanced diagnostic capabilities. Patients are increasingly prioritizing early detection and long-term management of respiratory conditions through specialized care and innovative therapies. The growing preference for advanced treatment options such as biologics, combination inhalation therapies, and minimally invasive procedures further propels the emphysema industry. Moreover, the increasing integration of digital health solutions, pulmonary rehabilitation programs, and personalized treatment approaches is significantly contributing to the market's expansion.

Europe Emphysema Market Insight

The Europe emphysema market is projected to expand at a steady CAGR throughout the forecast period, primarily driven by stringent healthcare regulations, rising awareness of respiratory diseases, and increasing demand for effective disease management solutions. The increase in aging population, coupled with higher rates of smoking and air pollution exposure in certain regions, is fostering the adoption of emphysema treatments. European healthcare systems emphasize early diagnosis and structured treatment pathways, supporting wider use of diagnostic tools and therapies. The region is experiencing notable growth across hospital and specialty care settings, with emphysema management being integrated into broader chronic disease programs.

U.K. Emphysema Market Insight

The U.K. emphysema market is anticipated to grow at a noteworthy CAGR during the forecast period, driven by increasing cases of COPD and a strong focus on public health initiatives targeting respiratory diseases. Additionally, concerns regarding smoking-related illnesses and air quality are encouraging early diagnosis and treatment adoption. The U.K.’s National Health Service (NHS) plays a key role in providing accessible treatment options, including medications and pulmonary rehabilitation services. The growing adoption of advanced therapies and structured care pathways is expected to continue supporting market growth in the country.

Germany Emphysema Market Insight

The Germany emphysema market is expected to expand at a considerable CAGR during the forecast period, fueled by rising awareness of chronic respiratory conditions and demand for advanced and efficient healthcare solutions. Germany’s well-developed healthcare infrastructure and strong emphasis on medical innovation promote the adoption of modern diagnostic techniques and treatment options. The integration of emphysema management into hospital-based care and specialty respiratory centers is increasingly prevalent. Additionally, a focus on precision medicine and high-quality clinical care aligns with local expectations, supporting the growth of emphysema therapies in the country.

Asia-Pacific Emphysema Market Insight

The Asia-Pacific emphysema market is poised to grow at the fastest CAGR during the forecast period of 2026 to 2033, driven by increasing air pollution levels, rising smoking rates, and growing awareness of respiratory diseases in countries such as China, India, and Japan. The region’s expanding population base and improving healthcare infrastructure are contributing to higher diagnosis and treatment rates. Furthermore, government initiatives aimed at improving healthcare access and respiratory health awareness are supporting market adoption. As APAC emerges as a key region for healthcare expansion, the accessibility and affordability of emphysema treatments are expected to improve significantly.

Japan Emphysema Market Insight

The Japan emphysema market is gaining momentum due to the country’s aging population, advanced healthcare system, and high awareness of chronic respiratory conditions. The increasing prevalence of COPD among elderly individuals is driving demand for effective long-term management solutions. Japan places strong emphasis on early diagnosis and preventive healthcare, leading to higher adoption of diagnostic tools such as spirometry and imaging tests. The integration of advanced therapies and structured treatment protocols in hospitals and specialty clinics is further fueling growth.

India Emphysema Market Insight

The India emphysema market accounted for the largest market revenue share in Asia Pacific in 2025, attributed to the country’s large population base, rising pollution levels, and increasing prevalence of smoking-related respiratory diseases. India is witnessing growing awareness about COPD and emphysema, supported by expanding healthcare access and government initiatives focused on respiratory health. The availability of affordable medications and increasing penetration of diagnostic facilities are key factors propelling the market. Additionally, improvements in healthcare infrastructure and the growth of specialty respiratory care centers are contributing to the expansion of emphysema treatment adoption in India.

Emphysema Market Share

The Emphysema industry is primarily led by well-established companies, including:

• AstraZeneca (U.K.)
• Teva Pharmaceutical Industries Ltd. (Israel)
• Novartis AG (Switzerland)
• GSK plc (U.K.)
• Pfizer Inc. (U.S.)
• Hikma Pharmaceuticals PLC (U.K.)
• Boehringer Ingelheim International GmbH (Germany)
• Orion Oyj (Finland)
• Verona Pharma plc (U.K.)
• Pulmonx Corporation (U.S.)
• Emphasys Medical Inc. (U.S.)
• Respinova Ltd (U.K.)
• Gala Therapeutics Inc. (U.S.)
• Pulmatrix Inc. (U.S.)
• Broncus Medical Inc. (U.S.)
• Holaira Inc. (U.S.)
• PneumRx Inc. (U.S.)
• Spiration Inc. (U.S.)
• Aeris Therapeutics Inc. (U.S.)

What are the Recent Developments in Global Emphysema Market?

• In November 2025, researchers reported promising outcomes from the first-in-human trial of permanent airway scaffolds for severe emphysema, showing significant lung function improvement and potential broader applicability than existing options in the BREATHE-3 study
• In September 2025, a major study published by the Radiological Society of North America found that emphysema detected via low-dose CT screening significantly predicts long-term mortality risk, reinforcing the importance of early imaging and preventive interventions
• In May 2025, clinical research published in Frontiers in Medicine provided updated insights into combined pulmonary fibrosis and emphysema, helping refine understanding of disease progression and management strategies in complex case
• In April 2025, research highlighted monoclonal antibody biologics such as benralizumab and dupilumab as breakthrough emphysema/COPD treatments that may improve inflammation control and reduce exacerbations compared with traditional therapies
• In January 2025, a Society of Thoracic Surgeons study presented at the STS Annual Meeting reported that lung volume reduction surgery (LVRS) for advanced emphysema may lead to better outcomes and fewer complications than endobronchial valve placement, influencing clinical decision-making

SKU-53908